GBA1 and synucleinopathy: Understanding the mechanistic links between GBA1 and synucleinopathy has driven development of therapeutic strategies centred on GCase augmentation, substrate reduction, chaperone therapy, gene therapy, and modification of downstream pathways (autophagy, lysosomes, lipids).